At a glance
- Originator Abbott Laboratories
- Class Antineoplastics; Benzoxazines; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Jan 2013 Discontinued for Cancer in USA (unspecified route)
- 08 Feb 2001 Profile reviewed but no significant changes made
- 23 Feb 1995 No-Development-Reported for Cancer in USA (Unknown route)